Table 1. PD-L1 expression levels of 870 breast cancer patients.
Variable | PD-L1 expression [n(%)] | P-valuea | |
---|---|---|---|
negative | Positive | ||
Medianage (years) | 47 (21-84) | ||
Tumor size(mm) | 0.002 | ||
≤20 | 238 (84.4) | 44 (15.6) | |
>20 | 38 (66.7) | 19 (33.3) | |
Stage | 0.257 | ||
I | 129 (83.2) | 26 (16.8) | |
II | 461 (77.2) | 136 (22.8) | |
III | 91 (77.1) | 27 (22.9) | |
Histologicalgradea | 0.013 | ||
1 | 32 (86.5) | 5 (13.5) | |
2 | 279 (82.5) | 59 (17.5) | |
3 | 370 (74.7) | 125 (25.3) | |
Positive lymph nodes | 0.533 | ||
0 | 334 (78.2) | 93 (21.8) | |
1–3 | 190(80.9) | 45 (19.1) | |
4–9 | 93 (76.9) | 28 (23.1) | |
≥10 | 64 (73.6) | 23 (26.4) | |
Lymph node ratio | 0.470 | ||
<0.20 | 169 (80.1) | 42 (19.9) | |
0.21≤xx<0.65 | 120 (78.4) | 33 (21.6) | |
>0.65 | 58 (73.4) | 21 (26.6) | |
Lymphovascular invasion | 0.015 | ||
No | 664 (78.8) | 179(21.2) | |
Yes | 16 (59.3) | 11 (40.7) | |
Receptor status | |||
Estrogen | <0.001 | ||
Positive | 570 (90.5) | 60 (9.5) | |
Negative | 111 (46.30) | 129 (53.8) | |
Progesterone | <0.001 | ||
Positive | 555 (90.0) | 62 (10.0) | |
Negative | 126 (49.8) | 127 (50.2) | |
her2 | 0.529 | ||
Negative | 668 (78.4) | 184 (21.6) | |
Positive | 13 (72.2) | 5 (27.8) | |
Ki67 indexb | 0.028 | ||
≤14% | 86 (69.9) | 37 (30.1) | |
>14% | 349 (79.3) | 91 (20.7) | |
Neo-adjuvant chemotherapy | 0.428 | ||
No | 625 (79.6) | 170 (21.4) | |
Yes | 56 (74.7) | 19 (25.3) | |
Chemotherapy | 0.109 | ||
No | 78 (84.8) | 14 (15.2) | |
Yes | 603 (77.5) | 175 (22.5) | |
Radiotherapy | 0.797 | ||
Yes | 521 (77.8) | 14 (22.2) | |
No | 23 (74.2) | 8 (25.8) | |
Endocrinetherapy | <0.001 | ||
No | 192 (61.9) | 118 (38.1) | |
Yes | 489 (87.3) | 71(12.7) | |
Subtypes | <0.001 | ||
Luminal A | 284 (88.5) | 37 (11.5) | |
Luminal B/HER2 negative | 287 (91.4) | 27 (8.6) | |
Luminal B/HER2 positive | 12 (92.3) | 1 (7.7) | |
Triple-negative | 98 (44.1) | 124 (55.9) |
her2, human epidermal growth factor receptor 2;
563 patients with known ki67expression.